Immunomodulation as innovative therapy for head and neck tumors. Current developments

被引：1
|
作者：
Schuler, P. J. [1 ]
Doescher, J. C. [1 ]
Laban, S. [1 ]
Hoffmann, T. K. [1 ]
机构：
[1] Univ Ulm Klinikum, Univ Klin Hals Nasen Ohrenheilkunde Kopf & Halsch, Frauensteige 12, D-89075 Ulm, Germany
来源：
HNO | 2016年 / 64卷 / 07期
关键词：
Head and neck neoplasms; Immunotherapy; Monoclonal antibodies; Programmed cell death 1 receptor; Vaccination; SQUAMOUS-CELL CARCINOMA; RECEPTOR FUSION PROTEIN; PHASE-I TRIAL; OPEN-LABEL; CANCER; RECURRENT; IMMUNOTHERAPY; DALANTERCEPT; COMBINATION; VACCINATION;
D O I：
10.1007/s00106-016-0131-0
中图分类号：
R76 [耳鼻咽喉科学];
学科分类号：
100213 ;
摘要：
Head and neck squamous cell carcinoma (HNSCC) is characterized by its intense immune suppression and its elaborate immune escape mechanisms. Due to the fact that survival rates remain low, the role of immunotherapy has become more important and the focus of current clinical studies has shifted toward antibody-based immune checkpoint modulation. Application of immunotherapy in curative settings or for prevention of recurrent disease would be desirable.
引用
收藏
页码：470 / 478
页数：9
相关论文
共 50 条
  • [21] Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy
    Smussi, Davide
    Mattavelli, Davide
    Paderno, Alberto
    Gurizzan, Cristina
    Lorini, Luigi
    Romani, Chiara
    Bignotti, Eliana
    Grammatica, Alberto
    Ravanelli, Marco
    Bossi, Paolo
    CANCER TREATMENT REVIEWS, 2023, 121
  • [22] New developments in radiation oncology for head and neck cancers
    Resl, Christoph
    Georg, Petra
    Doeller, Carmen
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, : 170 - 175
  • [23] Checkpoint inhibitors in head and neck cancer: current knowledge and perspectives
    Samra, Bachar
    Tam, Eric
    Baseri, Babak
    Shapira, Iuliana
    JOURNAL OF INVESTIGATIVE MEDICINE, 2018, 66 (07) : 1023 - 1030
  • [24] Immunotherapy in head and neck cancer: current practice and future possibilities
    Agada, F. O.
    Alhamarneh, O.
    Stafford, N. D.
    Greenman, J.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2009, 123 (01) : 19 - 28
  • [25] Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects
    Gao, Lei
    Zhang, Anqi
    Yang, Fuyuan
    Du, Wei
    VACCINES, 2022, 10 (08)
  • [26] Cisplatin-refractory germ cell tumors. Resistance mechanisms - therapy standards - new developments
    Oing, Christoph
    Seidel, Christoph
    Alsdorf, Winfried H.
    Bokemeyer, Carsten
    ONKOLOGE, 2017, 23 (02): : 123 - 128
  • [27] Renaissance of immuno-oncology for urological tumors. Current status
    Grimm, M. -O.
    Winkler, Y.
    Fetter, I.
    Oppel-Heuchel, H.
    UROLOGE, 2016, 55 (05): : 621 - 626
  • [28] Gene therapy for brain tumors: Basic developments and clinical implementation
    Assi, Hikmat
    Candolfi, Marianela
    Baker, Gregory
    Mineharu, Yohei
    Lowenstein, Pedro R.
    Castro, Maria G.
    NEUROSCIENCE LETTERS, 2012, 527 (02) : 71 - 77
  • [29] Recent developments in head and neck melanoma
    Deot, Neal
    Suryadevara, Amar
    CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2020, 28 (04) : 258 - 262
  • [30] Current State and Future Directions of EGFR-Directed Therapy in Head and Neck Cancer
    Tathineni, Praveena
    Joshi, Nikhil
    Jelinek, Michael J.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (06) : 680 - 692
12345